109 GENES FOUND

? »

Limit search: Genes with antibodies | Premium | Premium (Tissue) | Premium (Subcell) | Premium (Cell line)

« prev | Page of 3 | next »

Show / hide columns »

XML | RDF | TAB

Gene

 

 

Gene description

x

 

 

Protein class

x

 

 

 

 

Tissue

Subcell

Cell line

Cancer

 

 

 

 

 

 

 

RNA tissue category

x

 

 

 

 

 

 

 

 

 

 

 

 

 

 

IFNAR1Interferon (alpha, beta and omega) receptor 1Cancer-related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
IFNAR2Interferon (alpha, beta and omega) receptor 2Cancer-related genes
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Expressed in all
IFNGR1Interferon gamma receptor 1CD markers
Disease related genes
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
IFNGR2Interferon gamma receptor 2 (interferon gamma transducer 1)Disease related genes
FDA approved drug targets
Predicted membrane proteins
Expressed in all
IGF1RInsulin-like growth factor 1 receptorCancer-related genes
CD markers
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
RAS pathway related proteins
Expressed in all
IL11RAInterleukin 11 receptor, alphaDisease related genes
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
IL17AInterleukin 17ACancer-related genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Group enriched
IL1BInterleukin 1, betaCancer-related genes
Candidate cardiovascular disease genes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Tissue enhanced
IL1R1Interleukin 1 receptor, type ICancer-related genes
CD markers
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
IL2RAInterleukin 2 receptor, alphaCancer-related genes
CD markers
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Tissue enhanced
IL2RBInterleukin 2 receptor, betaCancer-related genes
CD markers
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
IL2RGInterleukin 2 receptor, gammaCancer-related genes
CD markers
Disease related genes
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Tissue enhanced
IL3RAInterleukin 3 receptor, alpha (low affinity)CD markers
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
IL6RInterleukin 6 receptorCancer-related genes
Candidate cardiovascular disease genes
CD markers
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
INSRInsulin receptorCD markers
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
RAS pathway related proteins
Expressed in all
ITGA2BIntegrin, alpha 2b (platelet glycoprotein IIb of IIb/IIIa complex, antigen CD41)Cancer-related genes
Candidate cardiovascular disease genes
CD markers
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Tissue enhanced
ITGA4Integrin, alpha 4 (antigen CD49D, alpha 4 subunit of VLA-4 receptor)Cancer-related genes
CD markers
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Predicted secreted proteins
Mixed
ITGALIntegrin, alpha L (antigen CD11A (p180), lymphocyte function-associated antigen 1; alpha polypeptide)CD markers
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
ITGAVIntegrin, alpha VCancer-related genes
CD markers
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Expressed in all
ITGB1Integrin, beta 1 (fibronectin receptor, beta polypeptide, antigen CD29 includes MDF2, MSK12)Cancer-related genes
CD markers
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
ITGB3Integrin, beta 3 (platelet glycoprotein IIIa, antigen CD61)Cancer-related genes
CD markers
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
LHCGRLuteinizing hormone/choriogonadotropin receptorDisease related genes
FDA approved drug targets
G-protein coupled receptors
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
M6PRMannose-6-phosphate receptor (cation dependent)FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Expressed in all
MC2RMelanocortin 2 receptor (adrenocorticotropic hormone)Disease related genes
FDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Tissue enriched
MPLMPL proto-oncogene, thrombopoietin receptorCancer-related genes
CD markers
Disease related genes
FDA approved drug targets
Predicted membrane proteins
Not detected
MR1Major histocompatibility complex, class I-relatedFDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Mixed
MS4A1Membrane-spanning 4-domains, subfamily A, member 1CD markers
Disease related genes
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Transporters
Group enriched
MS4A2Membrane-spanning 4-domains, subfamily A, member 2FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Mixed
OXTROxytocin receptorFDA approved drug targets
G-protein coupled receptors
Predicted intracellular proteins
Predicted membrane proteins
Tissue enhanced
PDGFRBPlatelet-derived growth factor receptor, beta polypeptideCancer-related genes
CD markers
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
RAS pathway related proteins
Mixed
PGFPlacental growth factorCancer-related genes
Candidate cardiovascular disease genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
RAS pathway related proteins
Tissue enhanced
PLATPlasminogen activator, tissueCancer-related genes
Candidate cardiovascular disease genes
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Mixed
PLAUPlasminogen activator, urokinaseCancer-related genes
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted secreted proteins
Expressed in all
PLAURPlasminogen activator, urokinase receptorCancer-related genes
CD markers
FDA approved drug targets
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
PLGPlasminogenCancer-related genes
Candidate cardiovascular disease genes
Disease related genes
Enzymes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Tissue enriched
PLIN3Perilipin 3FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Expressed in all
PRLRProlactin receptorDisease related genes
FDA approved drug targets
Predicted membrane proteins
Predicted secreted proteins
Tissue enhanced
PTH2RParathyroid hormone 2 receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Tissue enhanced
RAMP1Receptor (G protein-coupled) activity modifying protein 1FDA approved drug targets
Predicted membrane proteins
Mixed
RAMP2Receptor (G protein-coupled) activity modifying protein 2FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Predicted membrane proteins
Predicted secreted proteins
Mixed
RAMP3Receptor (G protein-coupled) activity modifying protein 3FDA approved drug targets
Predicted membrane proteins
Tissue enhanced
SCTRSecretin receptorFDA approved drug targets
G-protein coupled receptors
Predicted membrane proteins
Transporters
Group enriched
SERPINB2Serpin peptidase inhibitor, clade B (ovalbumin), member 2Cancer-related genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Tissue enhanced
SERPINC1Serpin peptidase inhibitor, clade C (antithrombin), member 1Candidate cardiovascular disease genes
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Tissue enriched
SERPIND1Serpin peptidase inhibitor, clade D (heparin cofactor), member 1Candidate cardiovascular disease genes
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Tissue enriched
SERPINE1Serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1Cancer-related genes
Candidate cardiovascular disease genes
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted secreted proteins
Tissue enhanced
SNAP25Synaptosomal-associated protein, 25kDaFDA approved drug targets
Predicted intracellular proteins
Transporters
Tissue enriched
SYT2Synaptotagmin IIFDA approved drug targets
Predicted membrane proteins
Tissue enhanced
TLR2Toll-like receptor 2CD markers
FDA approved drug targets
Predicted membrane proteins
Tissue enhanced
TNFTumor necrosis factorCancer-related genes
Candidate cardiovascular disease genes
Disease related genes
FDA approved drug targets
Plasma proteins
Predicted intracellular proteins
Tissue enhanced

« prev | Page of 3 | next »